Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.